Skip to content

Joint Injections for Osteoarthritic Knee Pain

The Efficacy of Prolotherapy in Osteoarthritic Knee Pain

Status
Completed
Phases
Phase 1Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00085722
Enrollment
98
Registered
2004-06-16
Start date
2004-07-31
Completion date
2016-05-01
Last updated
2019-02-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

Injection Therapy

Brief summary

The purpose of this study is to determine whether prolotherapy (PrT), a therapy based on injection of a sugar solution in and around the knee, can decrease pain and disability from knee osteoarthritis (OA).

Detailed description

OA is a common, debilitating condition for which there is no cure and no known cause. Prolotherapy (PrT) is an injection-based therapy for chronic musculoskeletal pain in which an irritant solution is injected at painful ligaments and tendons to produce stronger connective tissue and decrease pain. Although limited studies suggest PrT is effective may be effective for low back pain, its use has not been rigorously studied in human clinical trials for osteoarthritis. Participants in this study will be randomly assigned to receive one of three treatments: standard PrT, injections with a saline placebo, or a pamphlet with recommendations for home knee physical therapy. Injections will be given at Weeks 1, 5, and 9; injection group subjects will have the option to receive an additional 2 sets of injections. All participants will be assessed for a total of 1 year. A set of disease-specific and general quality-of-life questionnaires will be used to assess participants' outcomes . A randomized subset of participants (N=38)will receive magnetic resonance imaging (MRI)of the knee at baseline and 52 weeks. At study completion, participants who did not receive PrT will have the option to receive up to five sessions of PrT at no cost. Data will be collected for this group (minus MRI) and will be analyzed separately. Enrollment is limited to residents of Southern Wisconsin.

Interventions

Injection procedure: 50% dextrose is diluted with .9% 'normal' saline and 1% lidocaine to achieve 15% dextrose for ligament injections and 25% dextrose for intra-articular injection.

7 mL 9% 'normal' saline and 3mL 1% lidocaine

OTHERAt-home physical therapy exercise group

Subjects in the at-home physical therapy exercise group will receive a patient information pamphlet about knee osteoarthritis and conservative care instructions for standard at-home physical therapy exercises

Sponsors

National Center for Complementary and Integrative Health (NCCIH)
CollaboratorNIH
University of Wisconsin, Madison
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
40 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Pain from knee osteoarthritis that has impacted life for 3 months to 10 years * X-ray results indicating knee osteoarthritis

Exclusion criteria

* Knee osteoarthritis surgical candidate * History of total knee joint repair * Prior use of PrT * Prior fracture of the knee joint * Joint injection of steroids or other drugs within the past 3 months * Rheumatoid or inflammatory arthritis * Chronic use of narcotic medication * Other chronic pain diagnoses * diabetes mellitus * Body mass index (BMI) greater than 45 * Unresolved litigation * Pregnancy * Co-morbidity that may interfere with the study

Design outcomes

Primary

MeasureTime frame
Quality of life, pain scores and disability at wks 0, 5, 9, 12, 24, 52Participants will be followed for one year.

Secondary

MeasureTime frame
Secondary outcomes include disease and general quality of life indicators (all subjects) and magnetic resonance image (in a subset of 37 subjects).Participants will be monitored for one year.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026